^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    PhasED-Seq™ ctDNA assay

    Company:
    Foresight Diagnostics
    Type:
    Laboratory Developed Test
    Related tests:
    Details
    Evidence

    News

    10d
    Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy. (PubMed, J Clin Oncol)
    Liso-cel achieved deeper, more durable molecular clearance by ctDNA, consistent with superior EFS and PFS versus ASCT for second-line LBCL treatment. ctDNA-MRD provided prognostic value beyond PET, supporting its role as a complementary biomarker for treatment response and relapse prediction.
    Journal • Circulating tumor DNA
    |
    PhasED-Seq™ ctDNA assay
    |
    Breyanzi (lisocabtagene maraleucel)